Please assess the completion status of the following clinical trial:

Trial Title: JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Man or woman aged ≥ 18 years and \< 80 years~* Signed written informed consent~* Histologically confirmed diagnosis of locally advanced or metastatic predominantly transitional cell carcinoma of the urothelium (TCCU)~* Ineligibility for cisplatin-based therapy because of at least one of the following two medical conditions:~  * Calculated creatinine clearance (Cockcroft-Gault formula)\< 60 mL/min~ * New York Heart Association Classification Stage II-III Congestive Heart Failure (documented by medical history)~* Measurable disease with at least one uni-dimensional lesion according to RECIST guideline (version 1.1)~* ECOG performance status of 0 or 1~* Estimated life expectancy of at least 12 weeks~* Patient without prior systemic anticancer therapy unless if it had been administered as neoadjuvant or adjuvant chemotherapy (CT) for TCCU and if the patient has documented relapse ≥ 6 months after the last dose of CT (prior intravesical CT allowed)~* Adequate bone marrow and hepatic functions as evidenced by:~  * Absolute Neutrophil Count ≥ 2,000/mm3 (≥ 2.0 x 109/L)~ * Haemoglobin ≥ 10 g/dL~ * Platelet count ≥ 100,000/mm3~ * Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN)~ * Transaminases ≤ 2.5 x ULN \[≤ 5 x ULN only in case of liver metastasis\]~* Absence of psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; these conditions should be assessed with the patient before registration in the trial~Exclusion Criteria:~* ECOG performance status ≥ 2~* Woman if pregnant or lactating or with positive pregnancy test at inclusion; woman of child-bearing potential who did not use or is unwilling or unable to use an acceptable method to avoid pregnancy during the 2 months preceding the start of study treatment, for the entire study period and for up to 3 months after the last dose of study treatment; sexually active fertile man not using effective birth control during the study and up to 6 months after the last dose of study treatment if his partner is a woman of child-bearing potential~* Known brain metastasis or leptomeningeal involvement.~* Peripheral neuropathy Grade ≥ 2 by NCI CTC~* Prior radiation to ≥ 30% of the bone marrow or completed \< 30 days ago or without full recovery of toxicities~* Other serious illness or medical condition including:~  * Infection requiring systemic anti-infective therapy~ * Any medical condition that might not be controlled, for instance patients with unstable angina, patients with myocardial infarction within 6 months or uncontrolled diabetes~* Prior systemic chemotherapy for advanced or metastatic disease or neoadjuvant/adjuvant chemotherapy that was completed \< 6 months before documented progression~* Patient who had received any other investigational drug or anti-cancer therapy within 30 days before randomisation~* Other malignancies except adequately treated basal carcinoma of the skin, in-situ cervix carcinoma, localised prostate cancer with limited risk of recurrence (pT ≤ 2b, Gleason score ≤ 7) that was incidentally discovered and did not lead to any other treatment apart from prostatectomy, or any other tumor with a disease free interval ≥ 5 years~* Inadequate renal function defined by a serum creatinine clearance \< 30 mL/min (Cockcroft-Gault formula)~* Known hypersensitivity to the study drugs or to drugs with similar chemical structures~* Patients who require treatment with ketoconazole, itraconazole, ritonavir, amprenavir, indinavir, rifampicin (any potent CYP3A4 inhibitor or inducer) or phenytoin~* Any concurrent chronic system immune therapy or previous organ allograft~* Electrocardiogram (ECG) with significant modifications suggesting a high risk of occurrence of an acute clinical event

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Vinflunine plus Gemcitabine (Type: OTHER): None
- Vinflunine plus Carboplatin (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).